I found this:
Quote:
Vaccination against COVID-19 and the use of DMT in MS: future scenarios
A huge effort for the development of a vaccine against COVID-19 is ongoing worldwide, whose discussion in deeper detail is outside the scope of the present review.59 When safe and effective vaccination will be made available at the public, subjects at risk, included those affected by chronic diseases such as MS, should be given priority access. However, depending on the type of vaccine and on the ongoing DMT, not all MS patients will likely be immediately eligible. For instance, live attenuated vaccines are contraindicated during treatment with many DMTs.60 Moreover, several treatments affect the response to vaccination, particularly anti-CD20 drugs, but also fingolimod,61 with mixed evidence on natalizumab.When an inactivated vaccine will be available, strategies will have to be implemented, including, for instance, temporary de-escalation of MS patients to treatments that affect the response to vaccination less.
|
It is part of this article from Multiple Sclerosis Journal (November 18, 2020), "COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments":
SAGE Journals: Your gateway to world-class journal research